Zevra Therapeutics Dirección
Dirección controles de criterios 0/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Neil McFarlane
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 4.6% |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 1.3yrs |
| Promedio de permanencia en la Junta Directiva | 1.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensación vs. Mercado: La compensación total de Neil($USD3.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Neil con los resultados de la empresa.
CEO
Neil McFarlane (50 yo)
less than a year
Permanencia
US$3,445,231
Compensación
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$3.45m | sin datos | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.065% $ 136.9k | |
| CFO, Secretary & Treasurer | 8.9yrs | US$2.26m | 0.038% $ 79.9k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.3yrs | US$1.82m | 0.0084% $ 17.6k | |
| Chief Scientific Officer | 1.3yrs | US$1.08m | 0.0066% $ 13.8k | |
| Vice President of Investor Relations & Corporate Communications | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Manufacturing | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Medical Affairs & Advocacy | 1.3yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| Senior VP & Corporate Controller | 7.3yrs | sin datos | 0.011% $ 22.4k |
1.3yrs
Permanencia media
50.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ZVRA no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$3.45m | sin datos | |
| Independent Director | 1.1yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 2.8yrs | US$324.39k | 0.0017% $ 3.6k | |
| Member of Scientific and Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.1yrs | US$264.31k | 0.048% $ 100.6k | |
| Independent Director | 1.1yrs | US$260.67k | 0.0024% $ 5.0k | |
| Chairman of Scientific and Medical Advisory Board | 17.3yrs | sin datos | sin datos | |
| Member of Scientific & Medical Advisory Board | no data | sin datos | sin datos | |
| Co-Chair of Physician Advisory Council | 10.6yrs | sin datos | sin datos | |
| Co-Chair of Physician Advisory Council | 10.6yrs | sin datos | sin datos | |
| Independent Director | less than a year | US$243.04k | 0.024% $ 50.3k |
1.1yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de ZVRA no se considera experimentada (1 años de permanencia promedio), lo que sugiere una nueva junta directiva.